Shares of biopharma outfit Anavex Life Sciences (NASDAQ: AVXL) are up 17.2% as of early afternoon following a trial update for its flagship therapy ANAVEX 2-73. The drug, also called blarcamesine, prompted marked improvements in the cognitive capabilities of Parkinson’s disease patients.